Metabolic Tumor Volume Measured by 18F-FDG PET/CT is Associated with the Survival of Unresectable Hepatocellular Carcinoma Treated with PD-1/PD-L1 Inhibitors Plus Molecular Targeted Agents
Xuezhu Wang,Xu Yang,Jingnan Wang,Chengyan Dong,Jie Ding,Meiqi Wu,Yanyu Wang,Haiyan Ding,Hui Zhang,Xinting Sang,Haitao Zhao,Li Huo
DOI: https://doi.org/10.2147/JHC.S401647
2023-04-08
Journal of Hepatocellular Carcinoma
Abstract:Xuezhu Wang, 1, &ast Xu Yang, 2, &ast Jingnan Wang, 1 Chengyan Dong, 3 Jie Ding, 1 Meiqi Wu, 1 Yanyu Wang, 2 Haiyan Ding, 4 Hui Zhang, 4 Xinting Sang, 2 Haitao Zhao, 2 Li Huo 1 1 Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; 2 Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; 3 GE Healthcare China, Beijing, People's Republic of China; 4 Department of Biomedical Engineering, Tsinghua University, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Li Huo; Haitao Zhao, &num1 Shuaifuyuan, Dongcheng District, Beijing, People's Republic of China, Tel +86 13910801986; +86 13901246374, Email ; Purpose: The combination of PD-1/PD-L1 inhibitors and molecular targeted agents showed promising efficacy for unresectable hepatocellular carcinoma (uHCC). This study aimed to investigate the prognostic value of metabolic parameters from 18 F-fluorodeoxyglucose positron emission tomography-computed tomography ( 18 F-FDG PET/CT) in patients with uHCC underwent the combined therapies. Patients and Methods: Patients with uHCC treated with a combination of immunotherapy and targeted therapy who underwent baseline 18 F-FDG PET/CT between July 2018 and December 2021 were recruited retrospectively. The metabolic tumor volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake values (SUV max ), and clinical and biological parameters were recorded. A multivariate prediction model was developed for overall survival (OS) using these parameters together with clinical prognostic factors. Results: Seventy-seven patients were finally included. The median OS was 16.8 months. We found that a high MTV (≥ 39.65 cm 3 as the median value) was significantly associated with OS (P< 0.05). In multivariate analyses for OS, a high MTV, high Eastern Cooperative Oncology Group performance status (ECOG-PS, ≥ 1), Child-Pugh (B-C) grade, and the presence of bone metastasis were significantly associated with poor OS (HR 1.371, HR 3.73, HR 15.384, and HR 2.994, all P< 0.05, respectively). A multivariate prognostic model including MTV and prognostic factors, such as ECOG-PS, Child-Pugh grade, and bone metastasis, further improved the identification of different OS subgroups. Conclusion: High MTV is an adverse prognostic factor in patients with uHCC treated with a combination of immunotherapy and molecular targeted agents. Integrating PET/CT parameters with clinical prognostic factors could help to personalize immunotherapy. Graphical Keywords: unresectable hepatocellular carcinoma, PD-1 inhibitor, PD-L1 inhibitor, PET/CT, metabolic tumor volume, prognostic model Graphical Immune checkpoint inhibitor therapy or targeted monotherapy has recently shown considerable efficacy in unresectable hepatocellular carcinoma (uHCC). 1,2 Moreover, clinical studies have shown that the combination of anti-PD-1/PD-L1 immunotherapy with targeted therapy encourages efficacy in HCC. 3–7 However, only 10.7–37.4% of patients achieve an objective response. 8 Thus, there is a clear need for better patient selection before immunotherapy. 7,9 Despite significant efforts, only a few clinical, histological, and genetic parameters have been identified to reliably predict the efficacy of immunotherapy for uHCC. 9–12 In clinical practice, the utility of biomarkers based on tumor tissue is limited by the available tumor tissue due to spatial heterogeneity. 18 F-fluorodeoxyglucose positron emission tomography-computed tomography ( 18 F-FDG PET/CT), a non-invasive tool, has been shown to be a promising method for screening surveillance after treatment, evaluation of therapy response, and predicting the outcome. 13–15 In patients with uHCC, the highest metabolic activity within the tumor in a two-dimensional region of interest (ROI), as well as the metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in a three-dimensional ROI, are considered to provide valuable prognostic info -Abstract Truncated-
oncology